- Incyte to buy blood disorder drug in possibly $2B deal<figure><div><img src="https://imgproxy.divecdn.com/2QfDLQx7Ry-HALZnt9wJeCfUZIiqFEeEOc-a7yHR_O8/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzY2OTU4MDU4LmpwZ…BioPharma Dive · 1mo ago↗ source
- J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B<figure><div><img src="https://imgproxy.divecdn.com/8ktp2N_0bECPaVaqEXe_a9D0QIm8s6Dv94O0ycnj0SA/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9KSl9Mb2JieTAxX0hpZ2hSZXNfQzlXdTlwT…BioPharma Dive · 1mo ago↗ source
- Treeline to go public via reverse merger with Standard BioToolsTreeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The